Group 1 - The major shareholder and director, Cao Xuming, has completed his share reduction plan, which was set to expire [1] - Before the reduction, Cao Xuming held 13,807,449 shares, accounting for 11.5101% of the company [1] - The reduction plan disclosed on September 16, 2025, indicated a maximum reduction of 1,000,000 shares, representing 0.8336% of the total shares [1] Group 2 - From October 31, 2025, to January 6, 2026, Cao Xuming reduced his holdings by 970,000 shares through centralized bidding and block trading, which is 0.8086% of the total shares [1] - The total amount from the reduction was 86,346,078 yuan, with 30,000 shares remaining unfulfilled in the reduction plan [1] - Following the reduction, Cao Xuming's current shareholding percentage has decreased to 10.7015% [1]

龙芯中科公告称，截至2026年1月14日，持股5%以上股东宁波中科百孚创业投资基金合伙企业（有限合 伙）通过集中竞价减持115.14万股，使得其持股比例从6.01%降至5.73%，触及1%整数倍。此次减持是 履行此前减持计划，已实施完毕，不触及要约收购，不违反相关规定及承诺，也不会导致实控人变更和 对公司经营产生重大影响。 ...

Core Viewpoint - The major shareholders of Qusleep Technology (301336) have recently announced plans to reduce their holdings, raising concerns about the company's stock stability and potential changes in shareholder dynamics [1][2][3] Shareholder Reduction Plans - Two specific shareholders, Chengdu Kuanzhai Cultural Industry Investment Group (holding 4.01%) and Ningbo Panhuo Innovation Industry Investment Partnership (holding 0.6%), plan to reduce their stakes by a total of up to 2.61% within three months [1][3] - The anticipated cash from these reductions is estimated to exceed 58 million yuan based on the stock price of 56.96 yuan per share [1] Recent Shareholder Activity - Prior to the recent announcements, the controlling shareholders, including Chen Yaqiang and Xu Xiaobin, had already reduced their holdings by approximately 0.4281%, translating to around 10 million yuan [2] - In mid-October, other key shareholders reduced their stakes by 3.21%, resulting in a cash inflow of approximately 55.86 million yuan [2] Changes in Shareholding Structure - The overall shareholding of key shareholders has decreased from 35.63% to below 32%, which may alter the balance of power among shareholders [3] - The reduction by Kuanzhai Cultural Industry marks its first divestment since Qusleep's listing in 2022, indicating a potential shift in investment strategy from a state-owned entity [3] Market Performance and Future Outlook - Qusleep Technology's stock price has significantly declined, dropping over 40% from its peak of 100 yuan per share, which raises questions about the timing and motivation behind the shareholders' planned reductions [5] - Despite a 10.6% year-on-year revenue growth to 213 million yuan in the first three quarters of 2025, the company's growth rate has slowed compared to previous periods [5]

Core Viewpoint - The company Mengbaihe announced a share reduction by a major shareholder, Zhongyue Focus No. 9, which sold 4.1 million shares, representing 0.72% of the total share capital, reducing its stake from 8.68% to 7.96% [1] Group 1 - The share reduction occurred between January 8 and January 14, 2026 [1] - The reduction is part of a previously disclosed plan and does not trigger a mandatory tender offer [1] - The reduction will not lead to changes in the controlling shareholder or actual controller [1]

中国经济网北京1月14日讯 华森制药(002907.SZ)昨日晚间发布公告称，公司于近日收到公司控股股东成 都地方建筑机械化工程有限公司（以下简称"成都地建"或"控股股东"）及其一致行动人游洪涛、王瑛、 上海添橙投资管理有限公司－添橙添利一号私募证券投资基金（以下简称"添橙添利一号私募基金"） （以下合称"信息披露义务人"）出具的《简式权益变动报告书》。 本次权益变动前信息披露义务人合计持有华森制药股份292,317,525股，占华森制药总股本的70.00%。 2025年1月23日至2026年1月13日期间，成都地建通过集中竞价及大宗交易的方式减持华森制药股份 14,373,176股，占华森制药总股本3.44%；游洪涛通过大宗交易方式减持华森制药股份5,965,965股，占 华森制药总股本1.43%；添橙添利一号私募基金通过集中竞价方式减持华森制药股份540,780股，占华森 制药总股本0.13%。 2025年1月23日至2026年1月13日期间，华森制药的加权均价为16.894元/股，以此计算，信息披露义务 人合计减持华森制药20,879,921股，减持金额约为35,274.54万元。 本次权益变动前，信息 ...

公告显示，安阳启旭、河南翔宇健康产业管理有限公司同受公司实际控制人何永正、郭军玲夫妇控 制。 翔宇医疗于2021年3月31日在上交所科创板上市，发行数量为40,000,000股（全部为新股，不安排老 股转让），发行价格为28.82元/股，保荐机构为海通证券股份有限公司（现更名为国泰海通证券股份有 限公司），保荐代表人为刘君、岑平一。 翔宇医疗首次公开发行募集资金总额115,280.00万元；扣除发行费用后，募集资金净额为104,965.66 万元。翔宇医疗最终募集资金净额较原计划多34,165.66万元。翔宇医疗于2021年3月25日发布的招股说 明书显示，公司拟募集资金70,800.00万元，智能康复医疗设备生产技术改造项目、养老及产后康复医疗 设备生产建设项目、康复设备研发及展览中心建设项目、智能康复设备（西南）研销中心项目、运营储 备资金。 翔宇医疗发行费用总额10,314.34万元，其中保荐及承销费用7,939.04万元。 中国经济网北京1月14日讯 翔宇医疗(688626.SH)昨日晚间披露关于股东减持股份计划公告。 公司股东安阳启旭贸易咨询服务中心（有限合伙）（简称"安阳启旭"）持有公司股份 8, ...

Core Viewpoint - The major shareholder, Alibaba Health Technology (China) Co., Ltd., plans to reduce its stake in Shuyu Pingmin (301017) by up to 8,107,214 shares, representing 2% of the total share capital, due to personal funding needs [1][4]. Group 1: Shareholder Reduction Plans - Alibaba Health holds 27,039,100 shares, accounting for 6.67% of the company's total share capital [1]. - The reduction will occur within three months after the announcement, utilizing both centralized bidding and block trading methods [1]. - The planned reduction includes a maximum of 4,053,607 shares through centralized bidding and 4,053,607 shares through block trading, each not exceeding 1% of the total share capital [1]. Group 2: Previous Reductions - Alibaba Health previously reduced its stake by 7,040,900 shares from November 1 to December 12, 2024, with an average price of 13.53 yuan per share for centralized bidding and 11.69 yuan per share for block trading [5][6]. - The total reduction during this period accounted for 1.75% of the total share capital [5]. Group 3: Company Performance - For the first three quarters of 2025, the company reported total revenue of 7.446 billion yuan, a year-on-year increase of 5.19% [7]. - The net profit attributable to shareholders was 109 million yuan, marking a turnaround from losses [7]. - The company's stock price increased by 10.15% to 19.43 yuan per share as of January 13, 2025, with a total market capitalization of approximately 7.876 billion yuan [8].

股东减持股份结果公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏， 并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 证券代码：603997 证券简称：继峰股份 公告编号：2026-004 宁波继峰汽车零部件股份有限公司 注：因公司定向可转债"继峰定 01"在2025年11月存在转股，公司总股本相应增加，所以截至2026年1月 13日，余万立先生的持股比例从5.00%被动稀释至4.98%。 (二)本次减持是否遵守相关法律法规、本所业务规则的规定 √是 □否 ● 股东持股的基本情况：本次减持股份计划实施前，宁波继峰汽车零部件股份有限公司（以下简称"公 司"）股东余万立先生持有公司股份86,325,802股，占当时公司总股本的6.81%。 ● 减持计划的实施结果情况：公司于2026年1月13日收到股东余万立先生出具的《减持结果告知函》， 截至2026年1月13日，余万立先生通过大宗交易方式累计减持公司股份22,925,200股，占当时公司总股本 的1.81%。 一、减持主体减持前基本情况 ■ 上述减持主体无一致行动人。 二、减持计划的实施结果 (一)股 ...

港迪技术公告，嘉兴力鼎、松禾成长、翁耀根拟于披露后15个交易日后的减持期内通过集中竞价或大宗 交易各减持不超83.52万股，占1.5000%；汪贤忠拟通过集中竞价减持不超10万股，占0.1796%。嘉兴力 鼎减持窗口为60个自然日，松禾成长、翁耀根、汪贤忠减持窗口为2026年2月4日至2026年5月3日，减持 价格不低于发行价。 ...

华森制药公告称，2025年至2026年期间，控股股东成都地建、游洪涛、添橙添利一号私募基金实施减 持。变动前，三者合计持股2.92亿股，占总股本70%；期间，成都地建减持1437.32万股（占比 3.44%），游洪涛减持596.60万股（占比1.43%），添橙添利一号私募基金减持54.08万股（占比 0.13%）。变动后，三者合计持股2.71亿股，占比降至65%。本次减持不触及要约收购，不影响公司控 股权，部分减持计划未实施完毕。 ...